Institute for Drug Research, School of Pharmacy and David R. Bloom Center for Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Epilepsy Res. 2010 Dec;92(2-3):89-124. doi: 10.1016/j.eplepsyres.2010.09.001.
The Tenth Eilat Conference on New Antiepileptic Drugs (AEDs)-EILAT X, took place in Eilat, Israel from the 25th to 29th of April 2010. About 200 basic scientists, clinical pharmacologists and neurologists from 25 countries attended the conference, whose main themes included learning from the past: Lessons learnt after 18 years of Eilat Conferences and Detecting assessing and preventing adverse effects of AEDs. Consistent with previous formats of this conference, a large part of the program was devoted to a review of AEDs in development, as well as updates on AEDs introduced since 1994. Like the previous EILAT (EILAT IX) manuscript, the current (EILAT X) manuscript focuses only on the preclinical and clinical pharmacology of AEDs that are currently in development. These include brivaracetam, carisbamate, 2-deoxy-glucose, ganaxolone, huperizine A, ICA-105665, NAX-5055, retigabine, perampanel, T-2007, valnoctamide and YK3089. Since the previous Eilat Conference (EILAT IX-2008) two new AEDs; eslicarbazepine acetate and lacosamide have been marketed and three new AEDs in development not included in the EILAT IX manuscript were added: ICA-105665, perampanel and valnoctamide. The CNS efficacy of these compounds in anticonvulsant animal models as well as other disease model systems are presented in Tables 1 and 2 and their proposed mechanism of action at summarized in Table 3.
第十届埃拉特新型抗癫痫药物会议（AEDs）-EILAT X 于 2010 年 4 月 25 日至 29 日在以色列埃拉特举行。来自 25 个国家的约 200 名基础科学家、临床药理学家和神经病学家参加了会议，会议的主要主题包括：从过去中吸取教训：埃拉特会议 18 年后的经验教训；以及发现、评估和预防 AEDs 的不良反应。与该会议之前的形式一致，该计划的很大一部分致力于开发中的 AED 回顾，以及自 1994 年以来推出的 AED 更新。与之前的 EILAT（EILAT IX）手稿一样，当前的（EILAT X）手稿仅专注于目前正在开发的 AED 的临床前和临床药理学。这些包括布里瓦卡坦、卡利昔泮、2-脱氧葡萄糖、加奈索酮、石杉碱甲、ICA-105665、NAX-5055、雷替加滨、吡仑帕奈、T-2007、伐洛昔胺和 YK3089。自上次埃拉特会议（EILAT IX-2008 年）以来，两种新型 AED 已上市：依佐加滨醋酸盐和拉科酰胺，并且增加了三种未包含在 EILAT IX 手稿中的正在开发的新型 AED：ICA-105665、吡仑帕奈和伐洛昔胺。这些化合物在抗惊厥动物模型以及其他疾病模型系统中的中枢神经系统疗效在表 1 和 2 中呈现，其作用机制在表 3 中总结。
